Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

RotaTeq

- PMLiVE

GSK and Genmab file Arzerra for first-line use in US

Plans progress to expand the chronic lymphocytic leukaemia drug

- PMLiVE

Merck’s vintafolide shows its worth in ovarian cancer

Phase II data shows improvement on current oncology treatments

- PMLiVE

Janssen buys hepatitis C candidate from GSK

J&J subsidiary acquires rights to NS5A inhibitor

- PMLiVE

GSK hoping to file malaria vaccine next year

New phase III data backs submission plans

- PMLiVE

Merck’s anti-PD1 drug promising in lung cancer

Positive results in phase Ib trial

- PMLiVE

R&D in the firing line as Merck & Co axes 8,500 jobs

Shake up to boost research productivity

- PMLiVE

GSK sells off anticoagulants for £700m

South Africa-based Aspen buys rights to Arixtra and Fraxiparine

- PMLiVE

GSK’s Revolade cleared for use in hepatitis C therapy

Adds to drug’s existing thrombocytopenia indication

- PMLiVE

GSK’s Chinese sales hit by scandal, say analysts

Company estimated to have lost a third of its revenues

- PMLiVE

FDA rejects Merck muscle relaxant drug once again

Regulator still has hypersensitivity concerns about Bridion

- PMLiVE

GSK wins anthrax contract from US government

Signs $196m deal for its monoclonal anti-toxin raxibacumab

- PMLiVE

GSK antisense drug fails muscular dystrophy trial

Company and its partner Prosensa suffer setback with drisapersen

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links